Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells

Molecular Cancer Research

Volumn 6, Issue 7, 2008, Pages 1154-1168

  Chapman, Emma J ^a   Kelly, Gavin ^b   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CELL PROTEIN; HYDROXYPROSTAGLANDIN DEHYDROGENASE 15; KALLMANN SYNDROME 1 SEQUENCE; LYMPHOCYTE ANTIGEN 75; POLYCOMB GROUP PROTEIN; PROSTATE STEM CELL ANTIGEN; PROTEIN NME5; PROTEIN TSPYL5; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 1; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; TERT PROTEIN, HUMAN; UROPLAKIN II;

ARTICLE; BLOOD GROUP XG SYSTEM; CARCINOGENESIS; CELL DIFFERENTIATION; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; UROTHELIUM; CELL COUNT; CELL LINE; CELL PROLIFERATION; CULTURE MEDIUM; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; TELOMERE; TUMOR CELL LINE;

CELL COUNT; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; NEOPLASMS; STEM CELLS; TELOMERASE; TELOMERE; TRANSDUCTION, GENETIC; UROTHELIUM;

EID: 51649112247     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2168     Document Type: Article

References (67)

1. Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002;21:650-5.
2. Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 2006;25:5037-45.
3. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003;5:474-9.
4. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002;99:12606-11.
5. Zimmermann S, Martens UM. Telomeres and telomerase as targets for cancer therapy. Cell Mol Life Sci 2007;64:906-21.
6. Kraemer K, Fuessel S, Schmidt U, et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003;9:3794-800.
7. Sharma HW, Sokoloski JA, Perez JR, et al. Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A 1995;92:12343-6.
8. Bagheri S, Nosrati M, Li S, et al. Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A 2006;103:11306-11.
9. Alge CS, Hauck SM, Priglinger SG, Kampik A, Ueffing M. Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cytoskeletal remodeling and cell survival. J Proteome Res 2006;5:862-78.
10. Lindvall C, Hou M, Komurasaki T, et al. Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 2003;63:1743-7.
11. Ramirez RD, Sheridan S, Girard L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004;64:9027-34.
12. Farwell DG, Shera KA, Koop JI, et al. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol 2000;156:1537-47.
13. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 1997;94:13677-82.
14. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003;114:241-53.
15. Counter CM, Hahn WC, Wei W, et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 1998;95:14723-8.
16. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006;20:1123-36.
17. Maruyama K, Usami M, Aizawa T, Yoshikawa K. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells. Biochem Biophys Res Commun 1991;178:291-6.
18. Kuwako K, Taniura H, Yoshikawa K. Necdin-related MAGE proteins differentially interact with the E2F1 transcription factor and the p75 neurotrophin receptor. J Biol Chem 2004;279:1703-12.
19. Nowak K, Kerl K, Fehr D, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006;34:1745-54.
20. Varley CL, Stahlschmidt J, Lee WC, et al. Role of PPARγ and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci 2004;117:2029-36.
21. Harnden P, Allam A, Joyce AD, Patel A, Selby P, Southgate J. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995;27:169-74.
22. Varley CL, Stahlschmidt J, Smith B, Stower M, Southgate J. Activation of peroxisome proliferator-activated receptor-γ reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. Am J Pathol 2004;164:1789-98.
23. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994;71:583-94.
24. Choi J, Southworth LK, Sarin KY, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet 2008;4:e10.
25. Ringrose L. Polycomb comes of age: genome-wide profiling of target sites. Curr Opin Cell Biol 2007;19:290-7.
26. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A 2005;102:1859-64.
27. Furuyama T, Banerjee R, Breen TR, Harte PJ. SIR2 is required for polycomb silencing and is associated with an E(Z) histone methyltransferase complex. Curr Biol 2004;14:1812-21.
28. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40.
29. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 2007;450:440-4.
30. Davies HD, Leusink GL, McConnell A, et al. Myeloid leukemia in Prader-Willi syndrome. J Pediatr 2003;142:174-8.
31. Coppes MJ, Sohl H, Teshima IE, Mutirangura A, Ledbetter DH, Weksberg R. Wilms tumor in a patient with Prader-Willi syndrome. J Pediatr 1993;122:730-3.
32. Hashizume K, Nakajo T, Kawarasaki H, et al. Prader-Willi syndrome with del(15)(q11,q13) associated with hepatoblastoma. Acta Paediatr Jpn 1991;33:718-22.
33. Jaffray B, Moore L, Dickson AP. Prader-Willi syndrome and intratubular germ cell neoplasia. Med Pediatr Oncol 1999;32:73-4.
34. Taniura H, Taniguchi N, Hara M, Yoshikawa K. Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem 1998;273:720-8.
35. Nakada Y, Taniura H, Uetsuki T, Yoshikawa K. Characterization and chromosomal mapping of a human Necdin pseudogene. Gene 2000;245:185-91.
36. Brunelli S, Tagliafico E, De Angelis FG, et al. Msx2 and necdin combined activities are required for smooth muscle differentiation in mesoangioblast stem cells. Circ Res 2004;94:1571-8.
37. Tseng YH, Butte AJ, Kokkotou E, et al. Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin. Nat Cell Biol 2005;7:601-11.
38. Ohman Forslund K, Nordqvist K. The melanoma antigen genes - any clues to their functions in normal tissues? Exp Cell Res 2001;265:185-94.
39. Sigala S, Faraoni I, Botticini D, et al. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin Cancer Res 1999;5:1211-8.
40. Tabassum A, Khwaja F, Djakiew D. The p75(NTR) tumor suppressor induces caspase-mediated apoptosis in bladder tumor cells. Int J Cancer 2003;105:47-52.
41. Taniura H, Matsumoto K, Yoshikawa K. Physical and functional interactions of neuronal growth suppressor necdin with p53. J Biol Chem 1999;274:16242-8.
42. Taniura H, Kobayashi M, Yoshikawa K. Functional domains of necdin for protein-protein interaction, nuclear matrix targeting, and cell growth suppression. J Cell Biochem 2005;94:804-15.
43. Matsumoto K, Taniura H, Uetsuki T, Yoshikawa K. Necdin acts as a transcriptional repressor that interacts with multiple guanosine clusters. Gene 2001;272:173-9.
44. Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005;24:117-25.
45. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007;21:525-30.
46. van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007;52:455-63.
47. Tateishi K, Ohta M, Kanai F, et al. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 2006;12:6960-6.
48. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846-56.
49. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-21.
50. Nosrati M, Li S, Bagheri S, et al. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin Cancer Res 2004;10:4983-90.
51. Liu L, Berletch JB, Green JG, Pate MS, Andrews LG, Tollefsbol TO. Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol Cancer Ther 2004;3:1003-9.
52. Richardson RM, Nguyen B, Holt SE, Broaddus WC, Fillmore HL. Ectopic telomerase expression inhibits neuronal differentiation of NT2 neural progenitor cells. Neurosci Lett 2007;421:168-72.
53. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI, Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001;61:6592-600.
54. Giuliani L, Ciotti M, Stoppacciaro A, et al. UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 2005;13:185-91.
55. Bahrenberg G, Brauers A, Joost HG, Jakse G. Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 2000;275:783-8.
56. Tang S, Bhatia B, Maldonado CJ, et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 2002;277:16189-201.
57. Takazaki R, Nishimura I, Yoshikawa K. Necdin is required for terminal differentiation and survival of primary dorsal root ganglion neurons. Exp Cell Res 2002;277:220-32.
58. Chow NH, Liu HS, Chan SH. The role of nm23-1 in the progression of transitional cell bladder cancer. Clin Cancer Res 2000;6:3595-9.
59. Munier A, Serres C, Kann ML, et al. Nm23/NDP kinases in human male germ cells: role in spermiogenesis and sperm motility? Exp Cell Res 2003;289:295-306.
60. Al-Tubuly AA, Spijker R, Pignatelli M, Kirkland SC, Ritter MA. Inhibition of growth and enhancement of differentiation of colorectal carcinoma cell lines by MAb MR6 and IL-4. Int J Cancer 1997;71:605-11.
61. Yao M, Huang Y, Shioi K, et al. Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma. Clin Cancer Res 2007;13:152-60.
62. Vaughan MB, Ramirez RD, Wright WE, Minna JD, Shay JW. A three-dimensional model of differentiation of immortalized human bronchial epithelial cells. Differentiation 2006;74:141-8.
63. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
64. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
65. Smyth GK. Limma: linear models for microarray data. New York: Springer; 2005.
66. Gentleman R. Using GO for statistical analyses. Compstat 2004 Proceedings in Computational Statistics; 2004.
67. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007;26:5889-99.